SOST and chronic kidney disease: For example, serum sclerostin has been reported to increase in chronic kidney disease (CKD) and may contribute to the pathogenesis of chronic kidney disease–mineral and bone disorder (CKD‐MBD).5 Serum sclerostin levels are also higher in patients with cardiovascular disease and may predict cardiovascular mortality.6 A relationship with glucose metabolism has been suggested in light by reports of higher sclerostin levels in association with type 1 and type 2 diabetes mellitus in adolescents7 and adults,8 respectively.